AKVANO® expand_more
Pharma expand_more
Business scope expand_more

Company expand_more
Investors expand_more
- Investors expand_more
- Investerare expand_more
Media expand_more

AKVANO® expand_more
Pharma expand_more
Business scope expand_more

Company expand_more
Investors expand_more
- Investors expand_more
- Investerare expand_more
Media expand_more

Home / IR contact / IPO and prospectus

IR contact
Rights Issue 2024
Press releases
Financial reports
Financial calendar
Corporate governance
The share
- Shareholders
- Incentive program
IPO and prospectus
- TO1
Presentations
Subscribe

Investor menu

IR contact
Rights Issue 2024
Press releases
Financial reports
Financial calendar
Corporate governance
The share
- Shareholders
- Incentive program
IPO and prospectus
- TO1
Presentations
Subscribe

IPO and prospectus

Documents related to the company listing on Nasdaq First North 2019.

Company description as of 23 September 2019 (Swedish text only)

Presentations

IPO Teaser

The complete investment memorandum (A Swedish version)

The information on this website is of general information nature and is not intended to replace personal medical advice from doctors and other healthcare professionals. Lipidor’s pharma products are investigational drugs and are not approved for commercial use.

Privacy policy